Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Feron LJ"'
Autor:
Atkinson SJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Bagal SK; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Askin S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Chiarparin E; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Coen M; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Collie IT; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dale IL; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., De Fusco C; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dillman K; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Evans L; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Feron LJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Foster AJ; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Kantae V; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont S; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lynch JT; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Nilsson Lill S; Data Sciences & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden., Robb GR; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Saeh J; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Schimpl M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Scott JS; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Smith J; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Srinivasan B; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tentarelli S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Vazquez-Chantada M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Wagner D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Walsh JJ; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Watson D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4541-4559. Date of Electronic Publication: 2024 Mar 11.
Autor:
Kettle JG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Bodnarchuk MS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Boyd S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Braybrooke E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Breed J; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cosulich S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies NL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Deng C; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China., Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Feron LJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gleave ES; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cortés González MA; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Guerot C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Haider A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Harlfinger S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howells R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jackson A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Kemmitt PD; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Koers A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kondrashov M; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lewis HJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Liu L; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China., Mylrea M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Nash S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Peter A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Phillips C; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Pike K; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Raubo P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robb GR; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ross S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Schou M; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Simpson I; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Steward O; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Jul 13; Vol. 66 (13), pp. 9147-9160. Date of Electronic Publication: 2023 Jul 03.
Autor:
Cooper P; School of Chemistry, University of Bristol Bristol BS8 1TS UK., Dalling AG; School of Chemistry, University of Bristol Bristol BS8 1TS UK., Farrar EHE; Department of Chemistry, University of Bath Bath BA2 7AY UK M.N.Grayson@bath.ac.uk., Aldhous TP; School of Chemistry, University of Bristol Bristol BS8 1TS UK.; Department of Chemistry, University of Liverpool Crown Street Liverpool L69 7ZD UK john.bower@liverpool.ac.uk., Grélaud S; School of Chemistry, University of Bristol Bristol BS8 1TS UK., Lester E; School of Chemistry, University of Bristol Bristol BS8 1TS UK., Feron LJ; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca Cambridge UK., Kemmitt PD; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca Cambridge UK., Grayson MN; Department of Chemistry, University of Bath Bath BA2 7AY UK M.N.Grayson@bath.ac.uk., Bower JF; Department of Chemistry, University of Liverpool Crown Street Liverpool L69 7ZD UK john.bower@liverpool.ac.uk.
Publikováno v:
Chemical science [Chem Sci] 2022 Sep 13; Vol. 13 (37), pp. 11183-11189. Date of Electronic Publication: 2022 Sep 13 (Print Publication: 2022).
Autor:
Cooper P; School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK., Crisenza GEM; School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK., Feron LJ; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Bower JF; School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK.
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2018 Oct 22; Vol. 57 (43), pp. 14198-14202. Date of Electronic Publication: 2018 Sep 26.
Autor:
Grélaud S; School of Chemistry , University of Bristol , Bristol , BS8 1TS , United Kingdom., Cooper P; School of Chemistry , University of Bristol , Bristol , BS8 1TS , United Kingdom., Feron LJ; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge , United Kingdom., Bower JF; School of Chemistry , University of Bristol , Bristol , BS8 1TS , United Kingdom.
Publikováno v:
Journal of the American Chemical Society [J Am Chem Soc] 2018 Aug 01; Vol. 140 (30), pp. 9351-9356. Date of Electronic Publication: 2018 Jul 19.
Autor:
Weir HM; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom. Hazel.Weir@astrazeneca.com., Bradbury RH; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Lawson M; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Rabow AA; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Buttar D; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Callis RJ; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Curwen JO; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., de Almeida C; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Ballard P; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Hulse M; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Donald CS; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Feron LJ; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Karoutchi G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., MacFaul P; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Moss T; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Norman RA; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Pearson SE; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Tonge M; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Davies G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Walker GE; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Wilson Z; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Rowlinson R; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Powell S; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Sadler C; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Richmond G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Ladd B; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., Pazolli E; H3 Biomedicine, Cambridge, Massachusetts., Mazzola AM; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., D'Cruz C; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., De Savi C; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts.
Publikováno v:
Cancer research [Cancer Res] 2016 Jun 01; Vol. 76 (11), pp. 3307-18. Date of Electronic Publication: 2016 Mar 28.
Autor:
De Savi C; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.; Oncology iMed, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Bradbury RH; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Rabow AA; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Norman RA; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., de Almeida C; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Andrews DM; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Ballard P; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Buttar D; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Callis RJ; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Currie GS; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Curwen JO; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Davies CD; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Donald CS; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Feron LJ; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Gingell H; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Glossop SC; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Hayter BR; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Hussain S; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Karoutchi G; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Lamont SG; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., MacFaul P; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Moss TA; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Pearson SE; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Tonge M; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Walker GE; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Weir HM; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Wilson Z; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2015 Oct 22; Vol. 58 (20), pp. 8128-40. Date of Electronic Publication: 2015 Oct 07.